Published in Microbes Infect on February 11, 2012
Tularemia. Clin Microbiol Rev (2002) 8.51
Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A (2004) 7.30
The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat Genet (2005) 6.22
Structure and function of the LysR-type transcriptional regulator (LTTR) family proteins. Microbiology (2008) 3.68
Application of DNA microarrays to study the evolutionary genomics of Yersinia pestis and Yersinia pseudotuberculosis. Genome Res (2003) 2.51
Immunodominant Francisella tularensis antigens identified using proteome microarray. Proteomics (2007) 1.85
Pathogenesis of Yersinia pestis infection in BALB/c mice: effects on host macrophages and neutrophils. Infect Immun (2005) 1.73
From protein microarrays to diagnostic antigen discovery: a study of the pathogen Francisella tularensis. Bioinformatics (2007) 1.68
Direct repeat-mediated deletion of a type IV pilin gene results in major virulence attenuation of Francisella tularensis. Mol Microbiol (2006) 1.65
Inhibition of beta interferon transcription by noncytopathogenic bovine viral diarrhea virus is through an interferon regulatory factor 3-dependent mechanism. J Virol (2002) 1.56
Vaccines against Francisella tularensis. Ann N Y Acad Sci (2007) 1.46
The immunologically distinct O antigens from Francisella tularensis subspecies tularensis and Francisella novicida are both virulence determinants and protective antigens. Infect Immun (2006) 1.42
Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J Med Microbiol (2002) 1.37
A type IV pilin, PilA, Contributes To Adherence of Burkholderia pseudomallei and virulence in vivo. Infect Immun (2005) 1.34
Evidence of arbovirus co-infection in suspected febrile malaria and typhoid patients in Nigeria. J Infect Dev Ctries (2013) 1.28
Galleria mellonella as an alternative infection model for Yersinia pseudotuberculosis. Microbiology (2009) 1.23
Francisella tularensis vaccines. FEMS Immunol Med Microbiol (2007) 1.19
Structural characterization of lipo-oligosaccharide (LOS) from Yersinia pestis: regulation of LOS structure by the PhoPQ system. Mol Microbiol (2002) 1.15
Oral immunization with a dam mutant of Yersinia pseudotuberculosis protects against plague. Microbiology (2005) 1.08
Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun (2002) 1.05
Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun (2006) 1.02
The identification of surface proteins of Burkholderia pseudomallei. Vaccine (2006) 1.02
Induction of the Yersinia pestis PhoP-PhoQ regulatory system in the flea and its role in producing a transmissible infection. J Bacteriol (2013) 1.01
A dam mutant of Yersinia pestis is attenuated and induces protection against plague. FEMS Microbiol Lett (2005) 1.00
A 55 kDa hypothetical membrane protein is an iron-regulated virulence factor of Francisella tularensis subsp. novicida U112. J Med Microbiol (2007) 0.97
Differential processing of CD4 T-cell epitopes from the protective antigen of Bacillus anthracis. J Biol Chem (2003) 0.96
O-linked glycosylation of the PilA pilin protein of Francisella tularensis: identification of the endogenous protein-targeting oligosaccharyltransferase and characterization of the native oligosaccharide. J Bacteriol (2011) 0.93
Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica Serovar typhimurium. Infect Immun (2005) 0.92
Yersinia pseudotuberculosis mntH functions in intracellular manganese accumulation, which is essential for virulence and survival in cells expressing functional Nramp1. Microbiology (2010) 0.91
Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing a manno-heptose capsule. Clin Vaccine Immunol (2013) 0.90
Mechanisms of major histocompatibility complex class II-restricted processing and presentation of the V antigen of Yersinia pestis. Immunology (2006) 0.90
Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis. Open Biol (2013) 0.90
Particulate delivery systems for biodefense subunit vaccines. Adv Drug Deliv Rev (2005) 0.89
Characterisation of the immune response to the UK human anthrax vaccine. FEMS Immunol Med Microbiol (2003) 0.89
Glycosylation of DsbA in Francisella tularensis subsp. tularensis. J Bacteriol (2011) 0.89
Trimethoprim/sulfamethoxazole (co-trimoxazole) prophylaxis is effective against acute murine inhalational melioidosis and glanders. Int J Antimicrob Agents (2013) 0.88
Steps toward broad-spectrum therapeutics: discovering virulence-associated genes present in diverse human pathogens. BMC Genomics (2009) 0.87
A liquid-based method for the assessment of bacterial pathogenicity using the nematode Caenorhabditis elegans. FEMS Microbiol Lett (2002) 0.85
Development and application of the active surveillance of pathogens microarray to monitor bacterial gene flux. BMC Microbiol (2008) 0.85
A Francisella tularensis SCHU S4 mutant deficient in γ-glutamyltransferase activity induces protective immunity: characterization of an attenuated vaccine candidate. Microbiology (2011) 0.84
Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid). Vaccine (2005) 0.84
Liposome/DNA complexes coated with biodegradable PLA improve immune responses to plasmid encoding hepatitis B surface antigen. Immunology (2002) 0.84
VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. Vaccine (2005) 0.83
Experimental respiratory Marburg virus haemorrhagic fever infection in the common marmoset (Callithrix jacchus). Int J Exp Pathol (2013) 0.83
Immunogenicity of a Yersinia pestis vaccine antigen monomerized by circular permutation. Infect Immun (2006) 0.83
Deletion of the Bacillus anthracis capB homologue in Francisella tularensis subspecies tularensis generates an attenuated strain that protects mice against virulent tularaemia. J Med Microbiol (2010) 0.82
Influence of particle size on the pathology and efficacy of vaccination in a murine model of inhalational anthrax. J Med Microbiol (2010) 0.82
Potential of the beta-glucans to enhance innate resistance to biological agents. Expert Rev Anti Infect Ther (2010) 0.82
Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu. J Control Release (2005) 0.81
An intracellularly inducible gene involved in virulence and polyphosphate production in Francisella. J Med Microbiol (2008) 0.81
The efficacy of HSV-2 vaccines based on gD and gB is enhanced by the addition of ICP27. Vaccine (2012) 0.81
CpG used as an adjuvant for an adenovirus-based Venezuelan equine encephalitis virus vaccine increases the immune response to the vector, but not to the transgene product. Viral Immunol (2008) 0.81
Molecular recognition of chymotrypsin by the serine protease inhibitor ecotin from Yersinia pestis. J Biol Chem (2011) 0.81
The cationic peptide magainin II is antimicrobial for Burkholderia cepacia-complex strains. J Med Microbiol (2009) 0.80
An assessment of common marmoset (Callithrix jacchus) γ9(+) T cells and their response to phosphoantigen in vitro. Cell Immunol (2012) 0.80
Inhibition of Francisella tularensis LVS infection of macrophages results in a reduced inflammatory response: evaluation of a therapeutic strategy for intracellular bacteria. FEMS Immunol Med Microbiol (2011) 0.79
Development of rationally designed DNA N6 adenine methyltransferase inhibitors. Bioorg Med Chem Lett (2012) 0.79
Kinetic analysis of Yersinia pestis DNA adenine methyltransferase activity using a hemimethylated molecular break light oligonucleotide. PLoS One (2007) 0.79
Differences in membrane association and sub-cellular distribution between NS2-3 and NS3 of bovine viral diarrhoea virus. Virus Res (2003) 0.78
Structure and function of cytidine monophosphate kinase from Yersinia pseudotuberculosis, essential for virulence but not for survival. Open Biol (2012) 0.78
The designer proline-rich antibacterial peptide A3-APO prevents Bacillus anthracis mortality by deactivating bacterial toxins. Protein Pept Lett (2014) 0.77
The ability of CpG oligonucleotides to protect mice against Francisella tularensis live vaccine strain but not fully virulent F. tularensis subspecies holarctica is reflected in cell-based assays. Microb Pathog (2013) 0.77
Assessment of antimicrobial peptide LL-37 as a post-exposure therapy to protect against respiratory tularemia in mice. Peptides (2013) 0.77
Phenotypic characterization of a virulence-associated protein, VagH, of Yersinia pseudotuberculosis reveals a tight link between VagH and the type III secretion system. Microbiology (2007) 0.77
Differential role for interleukin-6 during Francisella tularensis infection with virulent and vaccine strains. Infect Immun (2013) 0.77
In vivo manipulation of γ9(+) T cells in the common marmoset (Callithrix Jacchus) with phosphoantigen and effect on the progression of respiratory melioidosis. PLoS One (2013) 0.76
A plague upon fibrin. Nat Med (2007) 0.76
Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model. FEMS Immunol Med Microbiol (2012) 0.76
Activation of dendritic cells by microparticles containing Bacillus anthracis protective antigen. Vaccine (2005) 0.76
Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection. Int J Antimicrob Agents (2009) 0.75
Animal usage in vaccine development and production: maximising results while minimizing use. Trends Microbiol (2002) 0.75
Modern Advances against Plague. Adv Appl Microbiol (2012) 0.75
CpG oligonucleotides protect against Venezuelan equine encephalitis virus infection in a route-dependent manner. Int J Antimicrob Agents (2013) 0.75
Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis for experimental murine melioidosis. Int J Antimicrob Agents (2010) 0.75
DNA adenine methylation. Adv Exp Med Biol (2003) 0.75